Welcome to the Podiatry Arena forums, for communication between foot health professionals about podiatry and related topics.
You are currently viewing our podiatry forum as a guest which gives you limited access to view all podiatry discussions and access our other features. By joining our free global community of Podiatrists and other interested foot health care professionals you will have access to post podiatry topics (answer and ask questions), communicate privately with other members (PM), upload content, view attachments, receive a weekly email update of new discussions, earn CPD points and access many other special features. Registered users do not get displayed the advertisments in posted messages. Registration is fast, simple and absolutely free so please, join our global Podiatry community today!
If you have any problems with the registration process or your account login, please contact contact us.
Press Release: Macrocure's CureXcell Shows Strong Efficacy and Safety in Phase IV Hard-To-Heal Wounds Trial
Quote:
Macrocure (www.macrocure.com), a biotechnology company developing and selling advanced cell therapy products, announced today it has achieved positive results for a “Real Life” Phase IV trial of its lead product, CureXcell®, for the treatment of hard-to-heal ulcers in a community care setting.
The recently-completed trial aimed to evaluate the safety and efficacy of CureXcell® for a variety of hard-to-heal ulcers and was conducted in 131 subjects at seven different clinics at the Clalit Heath Service facilities, Israel's largest HMO.
Trial results, presented at last week's Symposium on Advanced Wound Care (SAWC) Spring conference in Atlanta, Georgia, support the broad spectrum efficacy and safety of CureXcell, and included 68% and 81% and complete closure rates for diabetic foot ulcers (DFU) and venous ulcers, respectively, at 24 weeks. Overall the complete closure rate for all ulcers was about 71% and the median time to complete closure was about 12 weeks.
"The Macrocure team has worked extremely hard to develop and bring to market a cell therapy for hard-to-heal wounds, and we are confident that CureXcell is the best solution available today," said Mitchell Shirvan, chief executive officer of Macrocure. "This trial, in the community care setting, presented a truly challenging environment to test our therapy, and I am pleased with our results."
"Satisfying the primary objective for these studies in order to better define procedures and indices for wound healing in the HMO environment in the Phase IV clinical trial program signals significant progress in establishing the potential of CureXcell,” said Dr. Nicky Liebermann, Head, Community Medicine Division, Clalit Health Services. "This trial demonstrated both Clalit's and Macrocure's commitment to address the unmet needs of patients and improve their quality of life by providing innovative medicines and devices."
CureXcell is also currently undergoing a Phase III randomized, double-blind trial for lower extremity chronic ulcers in adults with diabetes in the United States, Canada and Israel. This product has marketing authorization in Israel for the treatment of chronic ulcers, but is not yet licensed for sale in either the United States or Canada.
CureXcell® is a novel approach to treating hard-to-heal wounds by replenishing the imbalanced inflammatory environment in non-healing wounds with a broad array of functionally-active allogeneic immune cells. These cells release the necessary cytokines and growth factors for the wound to heal. About 5,000 patients with various types and severities of hard-to-heal wounds have been treated in Israel and CureXcell® has been approved for reimbursement by the Israeli Ministry of Health.
CureXcell for hard-to-heal wounds
Linear Mode
